Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC for steroid-resistant GvHD
NCT02032446Phase 2Unknown
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Sep 2013
- Primary completion
- Sep 2016
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in graft-versus-host disease (GVHD), sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Vital parameters at 1 year. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02032446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02032446.